Is there still a future for neutral endopeptidase inhibitors?

Editorial

G S Francis. Am Heart J. 1999 Dec.

. 1999 Dec;138(6 Pt 1):1007-8.

doi: 10.1016/s0002-8703(99)70060-8.

No abstract available

Comment on

A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: the U.S. ecadotril pilot safety study.
O'Connor CM, Gattis WA, Gheorghiade M, Granger CB, Gilbert J, McKenney JM, Messineo FC, Burnett JC, Katz SD, Elkayam U, Kasper EK, Goldstein S, Cody RJ, Massie BM. O'Connor CM, et al. Am Heart J. 1999 Dec;138(6 Pt 1):1140-8. doi: 10.1016/s0002-8703(99)70081-5. Am Heart J. 1999. PMID: 10577446 Clinical Trial.
Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure.
Northridge DB, Newby DE, Rooney E, Norrie J, Dargie HJ. Northridge DB, et al. Am Heart J. 1999 Dec;138(6 Pt 1):1149-57. doi: 10.1016/s0002-8703(99)70082-7. Am Heart J. 1999. PMID: 10577447 Clinical Trial.